INFORMATION BY CANCER TYPE

Lymphoma

FDA Approves Rituxan Hycela for Blood Cancers
BY Jason M. Broderick
Rituxan Hycela (rituximab) was granted approval by the Food and Drug Administration (FDA) for adult patients with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma (DLBCL) and previously untreated and previously treated chronic lymphocytic leukemia (CLL).
Focusing on the Needs of AYA Patients With Lymphoma
BY Gina Columbus
Expert Lisa G. Roth, M.D., discusses the unique needs of AYA patients with Hodgkin lymphoma. 
Agent Shows Impressive Results for Diffuse Large B-Cell Lymphoma
BY Silas Inman
JCAR017 had promising complete response and objective response rates in treating patients with diffuse large B-cell lymphoma (DLBCL) in a recently presented study.
Expert Discusses Immunotherapy's Promise in Hodgkin Lymphoma
BY Danielle Bucco
Opdivo had promising response rates in a recent trial testing the treatment in patients with relapsed or refractory Hodgkin lymphoma.
Combination Is Promising and Tolerable for MCL
BY Brielle Urciuoli
Pairing two drugs that have shown to be effective in treating lymphoma might be the next step for mantle cell lymphoma treatment.
When the Bell Tolls for Another Loss to Cancer
BY Felicia Mitchell
When we are surviving cancer, when we want to see everybody else survive it too, another death is hard to take. When somebody passes, we are reminded of our own mortality—and distant losses—even as we mourn. Poetry helps.
Expert Discusses the Changing Landscape of Mantle Cell Lymphoma Treatment
BY Danielle Bucco
Peter Martin, M.D., discusses the evolving field of mantle cell lymphoma treatment.
Agent Granted Priority Review to Treat Non-Hodgkin Lymphoma
BY Silas Inman
Axicabtagene ciloleucel (KTE-C19; axi-cel) was granted a priority review by the Food and Drug Administration (FDA) for the treatment of transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma (NHL). 
Stem Cell Transplant Benefit Limited for Some Patients With Lymphoma
BY Angelica Welch
There is currently no uniform procedure for patients with double-hit lymphoma (DHL) that prolongs benefit. Some patients receive autologous stem-cell transplantation to reduce the risk of relapse, but the jury is still out on the impact that it has.
 
Copanlisib Granted Priority Review for Lymphoma
BY Jason M. Broderick
Copanlisib was granted a priority review designation by the Food and Drug Administratioin (FDA) for the treatment of patients with relapsed/refractory follicular lymphoma who had at least two therapies beforehand, according to Bayer, the manufacturer of the drug.
 
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Lymphoma CURE discussion group.
Search Cancer Drugs & Terms
Treatment
Information about treatment, including surgery, chemotherapy, radiation therapy, immunotherapy, and vaccine therapy
Adult Hodgkin Lymphoma Treatment (PDQ®)
Expert-reviewed information summary about the treatment of adult Hodgkin lymphoma.
Adult Non-Hodgkin Lymphoma Treatment (PDQ®)
Expert-reviewed information summary about the treatment of adult non-Hodgkin lymphoma.
AIDS-Related Lymphoma Treatment (PDQ®)
Expert-reviewed information summary about the treatment of AIDS-Related Lymphoma.
Childhood Hodgkin Lymphoma Treatment (PDQ®)
Expert-reviewed information summary about the treatment of childhood Hodgkin lymphoma.
Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)
Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma.
Primary CNS Lymphoma Treatment (PDQ®)
Expert-reviewed information summary about the treatment of primary CNS lymphoma.
x